Literature DB >> 23238272

Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery.

Julie Todoroff1, Bernard Ucakar, Malory Inglese, Sophie Vandermarliere, Catherine Fillee, Jean-Christophe Renauld, Kris Huygen, Rita Vanbever.   

Abstract

The current Bacille Calmette-Guérin vaccine provides variable protection against tuberculosis and new vaccination approaches are urgently needed. Pulmonary vaccination could be the best way to induce a protective immunity against Mycobacterium tuberculosis as it targets its natural site of infection. The aim of this study was to investigate the potential of Poloxamer 407 (P407) combined with a CpG oligonucleotide (CpG) to enhance immune responses to M. tuberculosis antigen 85A (Ag85A) following pulmonary delivery in BALB/c mice. An additional goal of this study was to localize the optimal delivery site of Ag85A within the lungs for generating the most intense immunity. We also investigated the capacity of P407 to prolong the residence time of the antigen within the lungs and we studied the safety of the adjuvants following pulmonary delivery. Targeting the antigen to the deep lungs produced more intense specific immune responses than targeting it to the upper airways. P407 and CpG further increased humoral immune responses and splenocyte proliferation in vitro. CpG strongly increased the Th-1 immune response with high IgG2a/IgG1 ratio, high IFN-γ and TNF-α productions by spleen mononuclear cells in vitro. P407 tended to induce a Th-2 response, as indicated by the slight decrease in IgG2a/IgG1 ratio and the slight increase in IL-5 levels. The combination of P407 and CpG produced the highest Th-1 and Th-17 responses by generating IFN-γ, TNF-α, IL-2, and IL-17A cytokines. Targeting the antigen to the deep lungs and the presence of P407 increased the residence time of the antigen within the lungs. This might explain the enhancement of immune responses induced by these factors. CpG did not induce inflammation in the lungs while P407 produced a reversible alteration of the alveolo-capillary barrier. Adding CpG to P407 did not further increase this alteration of the alveolo-capillary barrier. In conclusion, delivery of Ag85A formulated in a combination of P407 and CpG to the deep lungs induced strong immune responses, with a polyfunctional T cells phenotype.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238272     DOI: 10.1016/j.ejpb.2012.11.020

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation.

Authors:  Nitesh K Kunda; Iman M Alfagih; Sarah Rachel Dennison; Hesham M Tawfeek; Satyanarayana Somavarapu; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2014-10-09       Impact factor: 4.200

2.  Nanoparticle-mediated macrophage targeting-a new inhalation therapy tackling tuberculosis.

Authors:  Shaimaa Makled; Nabila Boraie; Noha Nafee
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

3.  Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.

Authors:  Julie Todoroff; Muriel M Lemaire; Catherine Fillee; Fabienne Jurion; Jean-Christophe Renauld; Kris Huygen; Rita Vanbever
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

4.  PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.

Authors:  Anneliese S Ashhurst; Thaigarajan Parumasivam; John Gar Yan Chan; Leon C W Lin; Manuela Flórido; Nicholas P West; Hak-Kim Chan; Warwick J Britton
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

Review 5.  Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.

Authors:  Farzad Khademi; Mohammad Derakhshan; Arshid Yousefi-Avarvand; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

6.  Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.

Authors:  Yoshita Bhide; Jasmine Tomar; Wei Dong; Jacqueline de Vries-Idema; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

7.  Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination.

Authors:  Jasmine Tomar; Wouter F Tonnis; Harshad P Patil; Anne H de Boer; Paul Hagedoorn; Rita Vanbever; Henderik W Frijlink; Wouter L J Hinrichs
Journal:  Acta Pharm Sin B       Date:  2019-05-28       Impact factor: 11.413

8.  T908 Polymeric Micelles Improved the Uptake of Sgc8-c Aptamer Probe in Tumor-Bearing Mice: A Co-Association Study between the Probe and Preformed Nanostructures.

Authors:  Romina Castelli; Manuel Ibarra; Ricardo Faccio; Iris Miraballes; Marcelo Fernández; Albertina Moglioni; Pablo Cabral; Hugo Cerecetto; Romina J Glisoni; Victoria Calzada
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.